Observational studyJournal of neurology2022

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.

Carmen Alcalá et al.PubMed ↗Publisher ↗

No numbers read from the abstract.